<DOC>
	<DOCNO>NCT01393158</DOCNO>
	<brief_summary>The purpose study obtain preliminary data regard safety tolerability apremilast AD support design large controlled study .</brief_summary>
	<brief_title>Apremilast Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Disease severity Moderate , Severe , Very Severe Investigator Global Assessment . Disease severity must great equal 6 RajkaLangeland Severity Scoring system correspond moderatesevere disease . Baseline EASI score must great equal 11 . A previous validation study EASI score system reveal patient moderate severe disease mean EASI score range 1130 . Candidate , previously systemic therapy , include cyclosporine , methotrexate , immunosuppressant treatment ultraviolet light . Specifically , subject consider candidate systemic therapy disease adequately control use topical therapy sideeffects prevent safe use topical therapy . Subjects must meet washout requirement History active mycobacterial infection specie ( include Mycobacterium tuberculosis ) within 3 year prior screen visit . Subjects Mycobacterium tuberculosis infection 3 year prior screen visit allow successful treatment complete least 3 year prior randomization document available verification . At least 3 major bacterial infection result hospitalization and/or require intravenous antibiotic treatment within past 2 year . Clinically significant abnormality chest Xray ( CXR ) screening . Chest Xrays perform within 3 month prior start study drug acceptable . Use investigational medication within 4 week prior start study drug 5 pharmacokinetic/pharmacodynamic halflives ( whichever longer ) . Any clinically significant abnormality 12lead ECG ( electrocardiogram ) screening . History congenital acquire immunodeficiency ( e.g. , Common Variable Immunodeficiency [ CVID ] ) . Hepatitis B surface antigen positive Hepatitis B core antibody positive screening . History Human Immunodeficiency Virus ( HIV ) infection . Antibodies Hepatitis C screen . History squamous cell carcinoma skin thin melanoma . Systemic corticosteroiddependent asthma . Active infection type time enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
</DOC>